Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

被引:304
作者
Yu, Helena A. [1 ]
Sima, Camelia S. [3 ]
Huang, James [2 ]
Solomon, Stephen B. [4 ]
Rimner, Andreas [5 ]
Paik, Paul [1 ]
Pietanza, M. Catherine [1 ]
Azzoli, Christopher G. [1 ]
Rizvi, Naiyer A. [1 ]
Krug, Lee M. [1 ]
Miller, Vincent A. [1 ]
Kris, Mark G. [1 ]
Riely, Gregory J. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, Thorac Oncol Serv, Div Solid Tumor Oncol,Dept Med, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, Thorac Serv, Dept Surg, New York, NY 10065 USA
[3] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, Dept Epidemiol & Biostat, New York, NY 10065 USA
[4] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, Dept Radiol, New York, NY 10065 USA
[5] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, Dept Radiat Oncol, New York, NY 10065 USA
关键词
EGFR-mutant lung cancer; Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors; Metastasectomy; Local therapy; PHASE-II TRIAL; MUTATIONS; GEFITINIB; CHEMOTHERAPY; CARBOPLATIN; PACLITAXEL; ERLOTINIB; NEVER; ADENOCARCINOMA; METASTASECTOMY;
D O I
10.1097/JTO.0b013e31827e1f83
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Development of acquired resistance limits the utility of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) for the treatment of EGFR-mutant lung cancers. There are no accepted targeted therapies for use after acquired resistance develops. Metastasectomy is used in other cancers to manage oligometastatic disease. We hypothesized that local therapy is associated with improved outcomes in patients with EGFR-mutant lung cancers with acquired resistance to EGFR TKI. Methods: Patients who received non-central nervous system local therapy were identified by a review of data from a prospective biopsy protocol for patients with EGFR-mutant lung cancers with acquired resistance to EGFR TKI therapy and other institutional biospecimen registry protocols. Results: Eighteen patients were identified, who received elective local therapy (surgical resection, radiofrequency ablation, or radiation). Local therapy was well tolerated, with 85% of patients restarting TKI therapy within 1 month of local therapy. The median time to progression after local therapy was 10 months (95% confidence interval [CI]: 2-27 months). The median time until a subsequent change in systemic therapy was 22 months (95% CI: 6-30 months). The median overall survival from local therapy was 41 months (95% CI: 26-not reached). Conclusions: EGFR-mutant lung cancers with acquired resistance to EGFR TKI therapy are amenable to local therapy to treat oligometastatic disease when used in conjunction with continued EGFR inhibition. Local therapy followed by continued treatment with an EGFR TKI is well tolerated and associated with long PFS and OS. Further study in selected individuals in the context of other systemic options is required.
引用
收藏
页码:346 / 351
页数:6
相关论文
共 40 条
[1]  
[Anonymous], NCCN CLIN PRACT GUID
[2]   MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J].
Bean, James ;
Brennan, Cameron ;
Shih, Jin-Yuan ;
Riely, Gregory ;
Viale, Agnes ;
Wang, Lu ;
Chitale, Dhananjay ;
Motoi, Noriko ;
Szoke, Janos ;
Broderick, Stephen ;
Balak, Marissa ;
Chang, Wen-Cheng ;
Yu, Chong-Jen ;
Gazdar, Adi ;
Pass, Harvey ;
Rusch, Valerie ;
Gerald, William ;
Huang, Shiu-Feng ;
Yang, Pan-Chyr ;
Miller, Vincent ;
Ladany, Marc ;
Yang, Chih-Hsin ;
Pao, William .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) :20932-20937
[3]   A 10-Year Single-Center Experience on 708 Lung Metastasectomies The Evidence of the "International Registry of Lung Metastases" [J].
Casiraghi, Monica ;
De Pas, Tommaso ;
Maisonneuve, Patrick ;
Brambilla, Daniela ;
Ciprandi, Barbara ;
Galetta, Domenico ;
Borri, Alessandro ;
Gasparri, Roberto ;
Petrella, Francesco ;
Tessitore, Adele ;
Guarize, Juliana ;
Donghi, Stefano Maria ;
Veronesi, Giulia ;
Solli, Piergiorgio ;
Spaggiari, Lorenzo .
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (08) :1373-1378
[4]   Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design [J].
Chaft, Jamie E. ;
Oxnard, Geoffrey R. ;
Sima, Camelia S. ;
Kris, Mark G. ;
Miller, Vincent A. ;
Riely, Gregory J. .
CLINICAL CANCER RESEARCH, 2011, 17 (19) :6298-6303
[5]   Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling [J].
Chmielecki, Juliann ;
Foo, Jasmine ;
Oxnard, Geoffrey R. ;
Hutchinson, Katherine ;
Ohashi, Kadoaki ;
Somwar, Romel ;
Wang, Lu ;
Amato, Katherine R. ;
Arcila, Maria ;
Sos, Martin L. ;
Socci, Nicholas D. ;
Viale, Agnes ;
de Stanchina, Elisa ;
Ginsberg, Michelle S. ;
Thomas, Roman K. ;
Kris, Mark G. ;
Inoue, Akira ;
Ladanyi, Marc ;
Miller, Vincent A. ;
Michor, Franziska ;
Pao, William .
SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (90)
[6]   Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy [J].
D'Amico, AV ;
Chen, MH ;
Roehl, KA ;
Catalona, WJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (02) :125-135
[7]   A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis [J].
Downey, RJ ;
Ng, KK ;
Kris, MG ;
Bains, MS ;
Miller, VA ;
Heelan, R ;
Bilsky, M ;
Ginsberg, R ;
Rusch, VW .
LUNG CANCER, 2002, 38 (02) :193-197
[8]  
Downey Robert J, 2006, Thorac Surg Clin, V16, P133, DOI 10.1016/j.thorsurg.2006.03.001
[9]   MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J].
Engelman, Jeffrey A. ;
Zejnullahu, Kreshnik ;
Mitsudomi, Tetsuya ;
Song, Youngchul ;
Hyland, Courtney ;
Park, Joon Oh ;
Lindeman, Neal ;
Gale, Christopher-Michael ;
Zhao, Xiaojun ;
Christensen, James ;
Kosaka, Takayuki ;
Holmes, Alison J. ;
Rogers, Andrew M. ;
Cappuzzo, Federico ;
Mok, Tony ;
Lee, Charles ;
Johnson, Bruce E. ;
Cantley, Lewis C. ;
Janne, Pasi A. .
SCIENCE, 2007, 316 (5827) :1039-1043
[10]  
Faehling M, 2012, J CLIN ONCOL S, V30